Imaging Test Using a CAIX-Targeted Probe for Kidney Cancer Patients

Who can take part

• Voluntary participation with the patient or their legal representative able to sign the informed consent form
• Adult patients (age between 18 and 75 years), regardless of gender
• Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging)
• Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment
• ECOG performance status score of 0-3
• Laboratory parameters must meet the following criteria:; ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal; Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L
• Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations

Who cannot take part

• Acute systemic diseases and electrolyte imbalances
• Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status)
• Patients or their legal representatives who are unable or unwilling to sign the informed consent form
• Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.)
• Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study